Breathe Well Live Well
|
Merck Announces Presentation of Phase III Investigational Studies Evaluating …
MarketWatch (press release) DULERA is indicated in the United States for the treatment of asthma in patients 12 years and older.(1) It is not indicated for the relief of acute bronchospasm or for the treatment of COPD. A supplemental new drug application (sNDA) for DULERA for the … |
View full post on asthma – Google News
|
MediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd …
MarketWatch (press release) Ltd., a pharmaceutical company traded on the Tokyo Stock Exchange (4547), will pay MediciNova $2.5 million, within 30 days, to support further clinical development of MN-221 for the treatment of acute exacerbations of asthma or chronic obstructive … |
View full post on asthma – Google News
|
MediciNova Closes $7.5 Million Private Stock Sale to Kissei Pharmaceutical Co …
MarketWatch (press release) MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, … |
View full post on asthma – Google News
|
Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide …
MarketWatch (press release) AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. In this double-blind, placebo-controlled study, … |
View full post on asthma – Google News
|
Latest Health and Wellness In-Car Technology from Ford to be Showcased Oct. 10 …
MarketWatch (press release) Ford is working with SDI Health and www.pollen.com to SYNC-enable its smartphone Allergy Alert app through AppLink, giving users voice-controlled access to the app that provides location-based day-by-day index levels for pollen; asthma, cold and cough … |
View full post on asthma – Google News
|
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma
MarketWatch (press release) If AstraZeneca chooses to advance the program following completion of Phase 2a, Dynavax will receive a $20 million milestone payment, and AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma … |
View full post on asthma – Google News
|
Teva Respiratory Provides Resources for Patients Impacted by PRIMATENE(R) MIST …
MarketWatch (press release) As a result of the removal of Primatene(R) Mist from the market, patients will need to see a healthcare professional to switch to another asthma medication. To help patients in this transition, Teva Respiratory is supporting patients through several … |
View full post on asthma – Google News
|
The National Center for Healthy Housing Praises Introduction of Bill to Create …
MarketWatch (press release) These risks include cancer, injuries, childhood lead poisoning and asthma that cost the country nearly $76 billion annually. Children and the elderly are the specific age group that are at the greatest risk. "We appreciate the leadership of Senators … |
View full post on asthma – Google News
|
Clinical Data Demonstrates Long-Term Safety of Boston Scientific's Alair[TM …
MarketWatch (press release) Follow-up data demonstrate that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with BT. Results were presented today at the annual European … Clinical Data Demonstrates Long-Term Safety of Boston Scientific's Alair[TM … |
View full post on asthma – Google News
|
Asthma and COPD Therapies: World Market 2011-2021
MarketWatch (press release) 26, 2011 /PRNewswire via COMTEX/ — Reportlinker.com announces that a new market research report is available in its catalogue: How will the market for asthma and COPD treatments perform from 2011? Our new report shows you potential drug revenues to … |
View full post on asthma – Google News